Clinical trials: Hepatocellular Carcinoma Recurrent
Hepatocellular Carcinoma
Value of Negative 18FDG PET/CT in Milan Out, Up-to-seven in, HCC Transplant Candidates
Hepatocellular carcinoma (HCC) is a rising public health concern with few curative options but liver transplantion (LT) in highly selected cases.
- Trial name
- NCT05276037
- Testing
- Liver transplantation
- Where
- 6 sites in Belgium
- Volunteers
- 350 people
- Sponsor
- University of Liege
Hepatocellular Carcinoma, Recurrence
Effect of Intraoperative Controlled Release 5-Fluorouracil Therapy on Recurrence in Hepatocellular Carcinoma Patients
The aim of this study is to confirmed the role of intraoperative controlled release 5-Fluorouracil therapy in the prevention of recurrence after surgery for HCC patients with high risk of preoperative prediction of microvascular…
- Trial name
- NCT02523053
- Testing
- Hepatectomy, 5-Fluorouracil
- Where
- China
- Volunteers
- 160 people
- Sponsor
- Eastern Hepatobiliary Surgery Hospital
Cancer Stem Cells, Postoperative Recurrence and Metastasis
Relationship Between Circulating Tumor Stem Cells and the Clinical Pathology
The aim of this study is to establish a platform of detecting and sorting circulating tumor stem cells from peripheral blood in HCC patients; to investigate the relationship between circulating tumor stem cells and their effects…
- Conditions
- Cancer Stem Cells, Postoperative Recurrence and Metastasis, Hepatocellular Carcinoma
- Trial name
- NCT02727673
- Where
- China
- Volunteers
- 1,000 people, healthy volunteers welcome
- Sponsor
- Eastern Hepatobiliary Surgery Hospital
Liver Cancer
Oxaliplatin, Capecitabine, and Cetuximab in Treating Patients With Advanced Liver Cancer
RATIONALE: Drugs used in chemotherapy, such as oxaliplatin and capecitabine, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing.
- Trial name
- NRR (NCT00483405)
- Testing
- cetuximab, capecitabine, oxaliplatin
- Where
- United States
- Volunteers
- 33 people
- Sponsor
- UNC Lineberger Comprehensive Cancer Center
Hepatocellular Carcinoma
Donafenib Combined With TACE as Adjuvant Therapy of Patients With Hepatocellular Carcinoma
The investigators design a phase IIB clinical study to explore the efficacy and safety of Donafenib combined with TACE as adjuvant therapy of patients with hepatocellular carcinoma at a high risk of recurrence after radical…
- Trial name
- NCT05161143
- Testing
- Donafenib
- Where
- China
- Volunteers
- 30 people
- Sponsor
- Peking Union Medical College Hospital
Solid Tumor, Lymphoma
Safety and Efficacy of p53 Gene Therapy Combined With Immune Checkpoint Inhibitors in Solid Tumors.
This is a single arm Phase 2 study of the combination of adenoviral p53 (Ad-p53) gene therapy administered intra-tumorally with approved immune checkpoint inhibitors in patients with recurrent or metastatic cancers.
- Trial name
- NCT03544723
- Testing
- Ad-p53
- Where
- 3 sites in United States
- Volunteers
- 40 people
- Sponsor
- MultiVir, Inc.
Hepatocellular Carcinoma
Clinical Research on Dynamic Monitoring MRD Via Plasma ctDNA After Systemic Therapy of Hepatocellular Carcinoma
This study aims to combine biomarker characteristic atlas and ctDNA detection technology to establish a precise standard scheme for minimal residual diagnosis of liver cancer after surgery and systemic treatment.
- Trial name
- NCT06178809
- Where
- China
- Volunteers
- 475 people
- Sponsor
- Singlera Genomics Inc.
Hepatocellular Carcinoma, RFA
Radiofrequency Ablation Combined With Transcatheter Arterial Chemoembolization Versus Radiofrequency Ablation Alone for Recurrent Hepatocellular Carcinoma
The combination of transcatheter arterial chemoembolization (TACE) with RFA has also reported to be an effective treatment for HCC.
- Conditions
- Hepatocellular Carcinoma, RFA, TACE
- Trial name
- NCT01415063
- Testing
- RFA, TACE-RFA
- Where
- China
- Volunteers
- 120 people
- Sponsor
- Sun Yat-sen University
Hepatocellular Carcinoma
A Multicenter Study of Anlotinib in Hepatocellular Carcinoma (HCC) Patients at High Risk of Post Surgery Recurrence
To assess the primary effects and safety of Anlotinib in HCC patients at high risk of post surgery recurrence.
- Trial name
- NCT03945799
- Testing
- Anlotinib Hydrochloride
- Where
- China
- Volunteers
- 28 people
- Sponsor
- Zhejiang University
Carcinoma, Hepatocellular
Adjuvant Chemotherapy With FOLFOX in HCC Patients After Resection
Hepatocellular carcinoma (HCC) is the sixth most common malignancies worldwide and the second leading cause of cancer-related death.
- Trial name
- NCT02738697
- Testing
- Adjuvant chemotherapy, Follow-up
- Where
- China
- Volunteers
- 290 people
- Sponsor
- Sun Yat-sen University
ORR,OS,PFS
Exploration of Sintilimab + Bevacizumab + AG Chemotherapy as First-Line Treatment for Unresectable Advanced/Metastatic Cholangiocarcinoma
Evaluation of Efficacy and Safety of Sintilimab Plus Bevacizumab and AG Regimen as First-Line Therapy in Patients with Surgically Ineligible Locally Advanced or Metastatic Cholangiocarcinoma Objectives: Primary Objective: To…
- Trial name
- NCT07328802
- Testing
- Sintilimab combined with bevacizumab and albumin-bound paclitaxel plus gemcitabine
- Where
- China
- Volunteers
- 25 people
- Sponsor
- Second Affiliated Hospital, Zhejiang University, School of Medicine
Hepatocellular Carcinoma (HCC)
Expanded Activated Lymphocytes (EAL) as Adjuvant Therapy in Patients With HCC at High Risk of Recurrence After Radical Resection
This is a multi-center, randomized, open-label pivotal phase II study to evaluate the efficacy and safety of EAL as adjuvant therapy in preventing recurrence in patients with primary HCC at high recurrence risk after radical…
- Trial name
- NCT05213637
- Testing
- Expanded Activated Lymphocytes (EAL), transarterial chemoembolization (TACE)
- Where
- China
- Volunteers
- 430 people
- Sponsor
- Chinese PLA General Hospital
Hepatocellular Carcinoma
Efficacy and Safety of Sitravatinib Plus Tislelizumab or Placebo Plus Tislelizumab Versus Placebo as Adjuvant Treatment in Participants With Hepatocellular Carcinoma
The purpose of this study is to compare the efficacy and safety of sitravatinib plus tislelizumab or placebo plus tislelizumab versus placebo.
- Trial name
- NCT05564338
- Testing
- Sitravatinib, Tislelizumab
- Sponsor
- BeiGene
Recurrent Liver Cancer, Primary Liver Cancer
Recurrent Liver Cancer: Reconceptualization and Reevaluation
The goal of this observational study is to determine if a specific protein can serve as a novel indicator for the recurrence of liver cancer.
- Trial name
- NCT06430983
- Where
- China
- Volunteers
- 300 people, healthy volunteers welcome
- Sponsor
- Nanjing Medical University
HCC
Artificial Intelligence and Hepatocellular Carcinoma
To identify new relevant biomarkers for HCC patients and their risk of recurrence. Radiomics data and computer-vision data will be explored for their ability to predict the presence of particular pathological signs of…
- Trial name
- ARTIHCC (NCT05637788)
- Testing
- CT Scan Radiomics Features Extraction
- Where
- Italy
- Volunteers
- 535 people
- Sponsor
- Humanitas Clinical and Research Center
Liver Transplantation, Hepatocellular Carcinoma
Impact of Postoperative Adjuvant Chemotherapy in Patients With Hepatocellular Carcinoma After Liver Transplantation
The study is designed to investigate the effect of postoperative adjuvant chemotherapy in prevention of tumor recurrence and metastasis for hepatocellular carcinoma after liver transplantation.
- Conditions
- Liver Transplantation, Hepatocellular Carcinoma, Tumor Recurrence and Metastasis, Survival
- Trial name
- NCT01125020
- Testing
- gemcitabine and oxaliplatin, doxorubicin, 5-Fu and cisplatin
- Where
- China
- Volunteers
- 150 people
- Sponsor
- Shanghai Jiao Tong University School of Medicine
Hepatocellular Carcinoma, Liver Cirrhosis
Study of Factors Predicting Tumor Recurrence After Liver Transplantation for Hepatocellular Carcinoma (HCC)
Results of liver transplantation, the best theoretical treatment for HCC, are limited by tumor recurrence. In order to limit this risk Milan criteria was proposed in 1996.
- Conditions
- Hepatocellular Carcinoma, Liver Cirrhosis, Evidence of Liver Transplantation
- Trial name
- EFAPRE (NCT01198704)
- Testing
- search of factors predicting tumor recurrence
- Where
- France
- Volunteers
- 372 people
- Sponsor
- Assistance Publique - Hôpitaux de Paris
Neoplasms
A Study of the Safety and Effects of ADH-1 Given Intravenously as a Single Agent
N-cadherin, a protein involved in blood vessel cell binding, is increased as cancer progresses, and is on the surface of many tumor cells. ADH-1 blocks N-cadherin.
- Trial name
- NCT00264433
- Testing
- ADH -1 (Exherin™)
- Where
- 11 sites in United States, Canada
- Sponsor
- Adherex Technologies, Inc.
Recurrent Hepatocellular Carcinoma
Tislelizumab or Tislelizumab Combined With Lenvatinib Neo-adjuvant Treatment for Resectable RHCC
This non-randomized phase II clinical trial aimed to explore the efficacy and safety of Tislelizumab or Tislelizumab combined with Lenvatinib as neoadjuvant treatment for resectable RHCC patients
- Trial name
- TALENT (NCT04615143)
- Testing
- Tislelizumab, Tislelizumab combined with Levatinib
- Where
- China
- Volunteers
- 80 people
- Sponsor
- Sun Yat-sen University
Resectable Hepatocellular Carcinoma
Tislelizumab Combined With Lenvatinib for Perioperative Treatment of Resectable Primary Hepatocellular Carcinoma
This is a prospective, one-arm, phase II clinical study of Tislelizumab combined with Lenvatinib for perioperative treatment of resectable primary hepatocellular carcinoma with a high risk of recurrence.
- Trial name
- NCT04834986
- Testing
- Tislelizumab combined with Lenvatinib
- Where
- China
- Volunteers
- 30 people
- Sponsor
- Tianjin Medical University Cancer Institute and Hospital